Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations

International Journal of Infectious Diseases

Volumn 17, Issue 11, 2013, Pages e939-e944

  Ott, J J ^a,b   Wiersma, S T ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Booster; Dosage; Hepatitis A virus; Inactivated vaccine

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS A; HUMAN; MALE; SHORT SURVEY; SINGLE DRUG DOSE; VACCINATION;

BOOSTER; DOSAGE; HEPATITIS A VIRUS; INACTIVATED VACCINE;

HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; VACCINATION;

EID: 84885381716     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.04.012     Document Type: Short Survey

References (25)

1. Jacobsen K.H., Wiersma S.T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010, 28:6653-6657.
2. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992, 327:453-457.
3. Iwarson S. Are we giving too many doses of hepatitis A and B vaccines?. Vaccine 2002, 20:2017-2018.
4. Iwarson S., Lindh M., Widerström L. Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 2002, 34:110-111.
5. Iwarson S., Lindh M., Widerström L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 2004, 11:120-121.
6. Mayorga Pérez O., Herzog C., Zellmeyer M., Loaisiga A., Frösner G., Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 2003, 188:671-677.
7. World Health Organization Meeting of the Strategic Advisory Group of Experts on Immunization, November 2011-conclusions and recommendations. Wkly Epidemiol Rec 2012, 1:15-16.
8. Ott J.J., Irving G., Wiersma S.T. Long-term protective effects of hepatitis A vaccines: a systematic review. Vaccine 2012, 31:3-11.
9. Vacchino M.N. Incidence of hepatitis A in Argentina after vaccination. J Viral Hepat 2008, 15(Suppl 2):47-50.
10. Sabanin I.V., Rikhter V.V., Kuzin S.N. [Assessment of effectiveness and immunogenicity of hepatitis A vaccination in servicemen of Internal Forces of Ministry of Internal Affairs of Russia] (in Russian). Zh Mikrobiol Epidemiol Immunobiol 2010, 1:35-39.
11. Bovier P.A., Farinelli T., Loutan L. Interchangeability and tolerability of a virosomal and an aluminium-adsorbed hepatitis A vaccine. Vaccine 2005, 23:2422-2427.
12. Shouval D., Ashur Y., Adler R., Lewis J.A., Armstrong M.E., Davide J.P., McGuire B., et al. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine 1993, 11(Suppl 1):S9-S14.
13. Cervio G., Trentadue J., D'Agostino D., Luque C., Giorgi M., Amoni J., Debbag R. Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program. Hepat Med 2011, 3:99-106.
14. Beck B.R., Hatz C., Brönnimann R., Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. Clin Infect Dis 2003, 37:126-128.
15. Hatz C., van der Ploeg R., Beck B.R., Frösner G., Hunt M., Herzog C. Successful memory response following a booster dose with a virosome-formulated hepatitis A vaccine delayed up to 11 years. Clin Vaccine Immunol 2011, 18:885-887.
16. ® in adults: safety, tolerability, and immunogenicity. Vaccine 2001, 19:4727-4731.
17. Landry P., Tremblay S., Darioli R., Genton B. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 2001, 19:399-402.
18. Lolekha S., Pratuangtham S., Punpanich W., Bowonkiratikachorn P., Chimabutra K., Weber F. Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in Thai children: comparison of three vaccine schedules. J Trop Pediatr 2003, 49:333-339.
19. Orr N., Klement E., Gillis D., Sela T., Kayouf R., Derazne E., et al. Long-term immunity in young adults after a single dose of inactivated hepatitis A vaccines. Vaccine 2006, 24:4328-4332.
20. Ellis A., Rüttimann R.W., Jacobs R.J., Meyerhoff A.S., Innis B.L. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev Panam Salud Publica 2007, 21:345-356.
21. Herzog C. EPAXAL®-Aluminium free. Presentation and personal communication at the SAGE Hepatitis A Working Group Meeting, Buenos Aires, Argentina, 2010.
22. Nalin D.R. VAQTA hepatitis A vaccine, purified inactivated. Drugs Fut 1995, 20:24-29. Prous Science Publishers, Barcelona, Spain.
23. Overbosch D., Peyron F., Picot N., Varichon J.P., Dumas R., Chambonneau L., Weber F. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J Travel Med 2005, 12:319-326.
24. Akimkin VG, Hepatitis A universal vaccination of military personnel: the Russian experience. Global Hepatitis A Meeting, Miami, USA, 2007. Available at:.(accessed February 3, 2012). http://www.docstoc.com/docs/47968689/EFFECTIVENESS-OF-UNIVERSAL-HEPATITIS-A-IMMUNIZATION-OF-YOUNG-CHILDREN.
25. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 2003, 362:1065-1071.